Boehringer Ingelheim Pharmaceuticals and Qualcomm have partnered to develop a connectivity solution for the Respimat inhaler to enhance chronic obstructive pulmonary disease (COPD) care.
Qualcomm Life is developing a prototype of small, wireless, low-power, disposable module for Boehringer Ingelheim's platform inhaler, through its 2net design platform.
The inhaler will connect with Qualcomm Life's 2net Platform, will be capable of tracking puffs from the Respimat inhaler.
2net, being developed by Qualcomm Life is a platform that designs communications components of connected medical devices which include disposable drug delivery devices as well as disposable diagnostic devices for condition specific connected therapies.
This collected data can be viewed by health care providers and patients prescribed with Boehringer Ingelheim’s RESPIMAT medicines.
A common habit among patients with COPD is following their treatment plans, which result in increased symptoms rates of COPD, health care costs, hospitalization and in some cases, can even be the cause of death.
With the collaboration, Boehringer Ingelheim wants to combine its expertise in developing COPD medicines with Qualcomm Life’s development designs in wireless, single-use and small integrated modules to create solutions that support adherence to daily treatment regimens.
Boehringer Ingelheim Pharmaceuticals Business Innovation Executive Director and Head Ruchin Kansal said: "For more than 40 years, Boehringer Ingelheim has had an unwavering commitment to the COPD community to provide new health solutions that can help improve patient outcomes and expand our understanding of COPD.
"Boehringer Ingelheim is proud to join forces with Qualcomm Life, a global leader in wireless technologies, to bring the latest technology to our Respimat inhaler with the goal of improving adherence to daily medicines that treat symptoms of COPD."